Carla D Kurkjian MD

Oncology•Oklahoma City, OK

Assistant Professor, Medicine, University of Oklahoma College of Medicine

Join to View Full Profile

4401 McAuley BlvdSte 2700Oklahoma City, OK 73120
Phone+1 405-751-4343
Fax+1 405-751-4346

Education & Training

University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Oklahoma College of MedicineClass of 2001

Certifications & Licensure

CA State Medical License 2009 - Present
OK State Medical License 2002 - 2025
TX State Medical License 2014 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
ACTIVE_NOT_RECRUITING
PHASE3
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide Start of enrollment: 2008 Mar 01
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer Start of enrollment: 2010 Nov 01
Terminated
Phase 1, Phase 2
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance Start of enrollment: 2011 Jan 01
Completed
Phase 3
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2011 Sep 19
Completed
Phase 1, Phase 2
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC Start of enrollment: 2013 Jun 19
Completed
Phase 1
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 Jun 19
TERMINATED
PHASE2
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
ACTIVE_NOT_RECRUITING
PHASE2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

65 citations
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I. Shapiro, Patricia LoRusso, E. L. Kwak, Susan Pandya, Charles M. Rudin
Investigational New Drugs. 2020-04-01
36 citations
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...
Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner
Investigational New Drugs. 2018-04-03
7 citations
Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide
John J. Krais, Needa A. Virani, Partick H. McKernan, Quang Nguyen, Kar Ming Fung
Molecular Cancer Therapeutics. 2017-09-01

Press Mentions

Former Volunteer Joins Mercy as Vice President of Cancer Services in OklahomaOctober 4th, 2016